Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model. - Wikidata - awgldk - TriplyDB

Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model.

Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model.

http://www.wikidata.org/entity/Q36072803

about

Clusterin: a key player in cancer chemoresistance and its inhibition Clusterin: Review of research progress and looking ahead to direction in hepatocellular carcinoma Clusterin protects hepatocellular carcinoma cells from endoplasmic reticulum stress induced apoptosis through GRP78.Indole-3- carbinol enhances sorafenib cytotoxicity in hepatocellular carcinoma cells: A mechanistic study Heat shock proteins in hepatocellular carcinoma: Molecular mechanism and therapeutic potential.GLI2 expression levels in radical nephrectomy specimens as a predictor of disease progression in patients with metastatic clear cell renal cell carcinoma following treatment with sunitinib.Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells.Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib.Characterization of mechanism involved in acquired resistance to sorafenib in a mouse renal cell cancer RenCa model.β4-integrin-mediated cytotoxic activity of AexU in human prostate cancer PC3 cells.Clusterin inhibition to enhance tumor chemosensitivity in systemic tumors.Effect of Targeting Clusterin Using OGX-011 on Antitumor Activity of Temsirolimus in a Human Renal Cell Carcinoma Model.Downregulating sCLU enhances the sensitivity of hepatocellular carcinoma cells to gemcitabine by activating the intrinsic apoptosis pathway.Enhanced sensitivity to sorafenib by inhibition of Akt1 expression in human renal cell carcinoma ACHN cells both in vitro and in vivo.

P2860

Q24567925-B6BEC7F2-E0F0-4579-8079-CC8F29B0418C Q26799048-8EB2B4B1-136F-44AB-84FE-6ECDA6328939 Q34606433-6CF68377-313B-4553-BD23-3F95E625070D Q37244398-A7FDEBE3-49B5-4BD8-93F2-1CE09109408F Q38725577-8E7763AB-14BB-45D3-AF0E-76FA9A84A96E Q38747792-FF2235DD-BB2D-488D-9BAE-2CF0C99B0C5E Q38817505-30CE8E72-8591-49A2-949F-CF1124DD4234 Q38936109-0326EE04-4C87-4CC4-9E09-15C1E39A1030 Q39041660-23B3F9CD-A061-449F-A63E-4AB70FC17E83 Q42926749-2F1221F1-5E3C-4072-8E70-E8D449066D58 Q44007986-475CFF88-42BB-46E8-86C9-FED361FA8E4A Q49116772-89FA8E29-4821-429E-8DF6-66AF325102C7 Q53060503-00DFE82E-9571-471E-96D4-16D837AFD7F9 Q55061628-D6191C6D-EFE2-45F2-941B-7C637E7CEB88

P2860

Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model.

http://www.wikidata.org/entity/Q36072803

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Clusterin inhibition using OGX ...... an renal cell carcinoma model.

@ast

Clusterin inhibition using OGX ...... an renal cell carcinoma model.

@en

type

label

Clusterin inhibition using OGX ...... an renal cell carcinoma model.

@ast

Clusterin inhibition using OGX ...... an renal cell carcinoma model.

@en

prefLabel

Clusterin inhibition using OGX ...... an renal cell carcinoma model.

@ast

Clusterin inhibition using OGX ...... an renal cell carcinoma model.

@en

P1433

Q36072803-735D2E4B-8D1E-4A3C-99D7-04CADCD4932F

P1476

Q36072803-E37DB1FF-7175-4D8A-B46E-0A6688975127

P2093

Q36072803-42559FB3-AE98-4DD5-873E-6FAB49B9CC0A

Q36072803-433ADF0F-27BE-45B5-8516-2887D0D87B25

Q36072803-69E05D09-5272-4ED1-BFDF-FAEC8100E05C

Q36072803-9C1A013D-DBB8-4442-A9C2-9CA33213D9E7

P2860

Q36072803-016796BC-4D86-4421-8E94-3C1C0C80EA1F

Q36072803-142DDA70-966E-4E3B-A8CD-6A0645EE81D0

Q36072803-1454F8C7-A454-4921-9E48-A82128478E4C

Q36072803-14AF2E8E-96A6-49C1-9E17-D31C1718EF9B

Q36072803-155FFCAD-0F16-4776-8D0B-56F2339F8FBA

Q36072803-1C954F50-A8FB-4F9D-BC45-62B9900D33A9

Q36072803-30BD67D8-FDEC-45CF-A392-453B7D6B54F3

Q36072803-47420136-C407-4C3B-A601-F05F9FBA081C

Q36072803-604956A9-A5E2-4605-A45B-4DFCFEBEEEE3

Q36072803-62B5BC7B-A6A7-4AB9-8818-E1DD67DE7CC7

P2888

Q36072803-742A81AB-2B00-49A1-8D18-57657AD007BF

P304

Q36072803-A310B70B-F7A3-40D1-91B3-61A90C534445

P31

Q36072803-5BCF0AEA-5242-4F36-8B64-B5B0616839C6

P356

Q36072803-39D482B2-FEA0-44C6-82DC-20E33DB9E2D2

P407

Q36072803-4B261513-398F-44E1-A77F-8A8A7C6A7D63

P433

Q36072803-D21D89E6-50FA-47E5-9A89-F0F2C300B00D

P478

Q36072803-CA4E6B33-74F1-4C52-ACC3-7FC52D139591

P577

Q36072803-D9A3DEE8-DA65-4711-AEC1-2A8048A7AFB7

P5875

Q36072803-02A77168-F8B6-415C-9630-F0628F41CE87

P698

Q36072803-5EEA538F-3EFB-4635-8BED-F9D88F7393DD

P932

Q36072803-BB1E68A8-53AF-4BA5-8FA4-BE7BA70A729B

P356

P1433

British Journal of Cancer

P1476

Clusterin inhibition using OGX ...... an renal cell carcinoma model.

@en

P2093

H Miyake

http://www.w3.org/2001/XMLSchema#string

M E Gleave

http://www.w3.org/2001/XMLSchema#string

M Fujisawa

http://www.w3.org/2001/XMLSchema#string

Y Kususda

http://www.w3.org/2001/XMLSchema#string

P2860

Clusterin facilitates COMMD1 and I-kappaB degradation to enhance NF-kappaB activity in prostate cancer cells

Clusterin inhibits apoptosis by interacting with activated Bax

Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models

Sorafenib in advanced clear-cell renal-cell carcinoma

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

Protection of androgen-dependent human prostate cancer cells from oxidative stress-induced DNA damage by overexpression of clusterin and its modulation by androgen.

Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer.

Therapeutic efficacy of adenoviral-mediated p53 gene transfer is synergistically enhanced by combined use of antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model.

Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin.

Clusterin silencing in human lung adenocarcinoma cells induces a mesenchymal-to-epithelial transition through modulating the ERK/Slug pathway.

P2888

P304

1945-1952

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2012.209

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224965875

http://www.w3.org/2001/XMLSchema#string

P698

22588555

http://www.w3.org/2001/XMLSchema#string

P932

3388571

http://www.w3.org/2001/XMLSchema#string